A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Public ClinicalTrials.gov record NCT04516278. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders, NORSE THREE
Study identification
- NCT ID
- NCT04516278
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Enrollment
- 195 participants
Conditions and interventions
Conditions
Interventions
- bevacizumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2020
- Primary completion
- Feb 9, 2021
- Completion
- Feb 9, 2021
- Last update posted
- Mar 18, 2025
2020 – 2021
United States locations
- U.S. sites
- 20
- U.S. states
- 10
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Site | Tucson | Arizona | 85710 | — |
| Clinical Site | Beverly Hills | California | 90211 | — |
| Clinical Site | Glendale | California | 91203 | — |
| Clinical Site | Long Beach | California | 90807 | — |
| Clinical Site | Palm Desert | California | 92260 | — |
| Clinical Site | Poway | California | 92064 | — |
| Clinical Site | Clearwater | Florida | 33761 | — |
| Clinical Site | Winter Haven | Florida | 33880 | — |
| Clinical Site | Oak Forest | Illinois | 60452 | — |
| Clinical Site | Springfield | Illinois | 62704 | — |
| Clinical Site | Hagerstown | Maryland | 21740 | — |
| Clinical Site | Albuquerque | New Mexico | 87109 | — |
| Clinical Site | Chambersburg | Pennsylvania | 17201 | — |
| Clinical Site | Rapid City | South Dakota | 57701 | — |
| Clinical Site | Germantown | Tennessee | 38138 | — |
| Clinical Site | Abilene | Texas | 79606 | — |
| Clinical Site | Arlington | Texas | 76012 | — |
| Clinical Site | McAllen | Texas | 78503 | — |
| Clinical Site | San Antonio | Texas | 78251 | — |
| Clinical Site | Willow Park | Texas | 76087 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04516278, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 18, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04516278 live on ClinicalTrials.gov.